(Q40047751)

English

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

scientific article published on 11 September 2008

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

multicenter clinical trial

0 references

multiple sclerosis

0 references

0 references

Frederik Barkhof

2

object named as

Frederik Barkhof

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

author name string

Daniel D Mikol

1

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

Peter Chang

3

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

Patricia K Coyle

4

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

Douglas R Jeffery

5

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

Steven R Schwid

6

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

Bettina Stubinski

7

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

Bernard M J Uitdehaag

8

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

REGARD study group

9

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

11 September 2008

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

Lancet Neurology

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

903-914

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

The immunopathology of multiple sclerosis: an overview

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970200-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970200-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Defining the clinical course of multiple sclerosis: Results of an international survey

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970200-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970200-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970200-X

7 January 2021

based on heuristic

inferred from DOI database lookup

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970200-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970200-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970200-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970200-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970200-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Accurate, robust, and automated longitudinal and cross-sectional brain change analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970200-X

7 January 2021

based on heuristic

inferred from DOI database lookup

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970200-X

7 January 2021

based on heuristic

inferred from DOI database lookup

A prospective, open-label treatment trial to compare the effect of IFN beta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970200-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: final comparative results of the EVIDENCE trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970200-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970200-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Evidence of interferon beta-1a dose response in relapsing-remitting MS: the OWIMS Study. The Once Weekly Interferon for MS Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970200-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970200-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Benefit of interferon beta-1a on MSFC progression in secondary progressive MS.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970200-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970200-X

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970200-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Ethics of placebo-controlled clinical trials in multiple sclerosis: a reassessment

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970200-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Importance of benefit-to-risk assessment for disease-modifying drugs used to treat MS.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970200-X

7 January 2021

based on heuristic

inferred from DOI database lookup

The measurement and clinical relevance of brain atrophy in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970200-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Acute Delirium, Delusion, and Depression During IFN-β-1a Therapy for Multiple Sclerosis: A Case Report

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970200-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Depression in multiple sclerosis associated with interferon beta-1a (Rebif).

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970200-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Cross-reactions and specificities of monoclonal antibodies against myelin basic protein and against the synthetic copolymer 1

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970200-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1474-4422(08)70200-X

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40047751&oldid=1883277419"